<DOC>
	<DOCNO>NCT02799121</DOCNO>
	<brief_summary>This prospective case series gain additional clinical experience treatment diabetic foot ulcer , document relate patient history ( include baseline wound characteristic ) clinical outcome ( incidence healing , rate healing , patient physician satisfaction ) group study participant ReGenerCell™ Autologous Cell Harvesting Device ( ReGenerCell™ ) use combination conventional therapy closure diabetic foot ulcer ( DFUs ) . Participants receive ReGenerCell™ treatment addition standard care ( debridement , cleanse , dressing , offload ) .</brief_summary>
	<brief_title>A Feasibility Study ReGenerCell™ Autologous Cell Harvesting Device Diabetic Foot Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>The patient stable diabetes mellitus accord investigator clinical judgement Diabetic foot Ulcer Groups 1 2 : Ulcer surface area 6 cm2 100 cm2 ( inclusive ) Group 1 : 1224 week duration , directly visible tendon bone ( University Texas Ulcer grade 1A ) Group 2 : &gt; 3 week duration , University Texas Ulcer grade 1B , 2A , 2B , 3A , 3B No superficial skin infection ( ulcer area ) require intervention Adequate offload compliance must achievable The patient 18 year age older The patient willing complete followup evaluation require study protocol The patient able abstain nonstandard treatment ulcer duration study , unless medically necessary The patient agree abstain enrolment interventional clinical trial duration study The patient able read understand instruction give voluntary write informed consent The patient able willing follow protocol Patients require intervention Peripheral Arterial Disease ( PAD ) exclude study Severe Peripheral Arterial Disease reconstructible Pregnant/lactating female ( selfreported test , per institutional requirement Use noninert dressing ( silver , honey etc . ) past 10 day Subjects evidence connective tissue disorder ( e.g . vasculitis rheumatoid arthritis ) active treatment The patient know preexist active condition may interfere wound healing , e.g . malignancy , autoimmune disease , immunocompromised blood borne disease , patient AIDS , HIV HepatitisC positive , currently severe dermatological disorder ( e.g . severe psoriasis , epidermolysis bullosa , pyoderma gangrenosum ) . The patient taking , take past 60 day , &gt; 10mg corticosteroid per day . The patient concurrent condition opinion investigator may compromise patient safety study objectives The patient know hypersensitivity trypsin Compound Sodium Lactate solution . The patient vulnerable protect adult The patient unable follow protocol The patient unable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>